Quality

Aireon Launches Safety Dashboard

Retrieved on: 
Monday, March 18, 2024

MCLEAN, Va., March 18, 2024 /PRNewswire/ -- Aireon is ushering in a new era of data analytics with the release of the first of its Data Dashboard products – Safety Dashboard.

Key Points: 
  • Aireon Safety Dashboard is a powerful tool designed to help ANSPs identify, monitor, and analyze key leading indicators of risk in their airspace.
  • "The Aireon Safety Dashboard is a great example of how we can work together leveraging existing data, to enhance our industry's safety efforts.
  • The Aireon Safety Dashboard is the first in a series of operational data dashboards to be developed by Aireon.
  • Aireon will demonstrate the Safety Dashboard at Airspace World event in Geneva, Switzerland from March 19-21.

Apptronik and Mercedes-Benz Enter Commercial Agreement That Will Pilot Apptronik's Apollo Humanoid Robot in Mercedes-Benz Manufacturing Facilities

Retrieved on: 
Friday, March 15, 2024

AUSTIN, Texas, March 15, 2024 /PRNewswire/ -- Apptronik, a leader in next-generation general purpose humanoid robots designed to change the way we live and work, today announced that it has entered into an agreement with Mercedes-Benz. As part of the agreement Apptronik and Mercedes-Benz will collaborate on identifying applications for highly advanced robotics in Mercedes-Benz Manufacturing.

Key Points: 
  • As part of the agreement Apptronik and Mercedes-Benz will collaborate on identifying applications for highly advanced robotics in Mercedes-Benz Manufacturing.
  • Mercedes-Benz is committed to empowering its staff with state-of-the-art technology that supports its commitment to excellence, and with Apollo , Mercedes-Benz brings one of the world's most advanced commercial humanoid robots into its manufacturing facilities.
  • Apollo will also be used to deliver the totes of kitted parts later in the manufacturing process.
  • "When we set out to build Apollo, an agreement like the one we're announcing today with Mercedes-Benz was a dream scenario," said Jeff Cardenas, co-founder & CEO of Apollo.

Doubleview Gold Corp. Announces Significant Copper and Gold Intervals, Including 6.94% Copper and 8.29 g/t Gold (11.27% Cu Eq[-Sc]) Over 4 meters, from South Lisle and Main Lisle Zones of Hat Porphyry Polymetallic Deposit

Retrieved on: 
Monday, February 26, 2024

Drill holes H067 and H068 in the South Lisle Zone returned very significant intervals of copper and gold values that add important length and grade dimensions to the porphyry deposit.

Key Points: 
  • Drill holes H067 and H068 in the South Lisle Zone returned very significant intervals of copper and gold values that add important length and grade dimensions to the porphyry deposit.
  • In addition to copper and gold, the Hat Deposit contains several critical metals, including Cobalt, and Scandium.
  • A 4 meter section of hole H067 returned a remarkable 6.94% copper and 8.29 g/t gold (11.27% Cu Eq[-Sc] "Cu Eq calculated excluding Sc content").
  • When completed the MRE will be published and mark a very material progression in our development of the Hat deposit".

MAPS Provides Psychedelic Crisis Assessment and Intervention Training to Denver’s First Responders

Retrieved on: 
Monday, March 11, 2024

MAPS uses its over 30 years of experience in the psychedelic space to offer a gold-standard training program.

Key Points: 
  • MAPS uses its over 30 years of experience in the psychedelic space to offer a gold-standard training program.
  • MAPS looks to share this training with other interested jurisdictions.
  • SAN JOSE, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies (MAPS) has partnered with the City and County of Denver to provide comprehensive training on psychedelic crisis assessment and intervention to the city’s first responders.
  • MAPS’ training aims to enhance the knowledge, attitudes, and skills of first responders to quickly recognize and effectively respond to emotional and behavioral crisis incidents involving psilocybin and other psychedelics.

Crosschq Ranks No. 7 on Inc. Magazine’s List of the Pacific Region’s Fastest-Growing Private Companies  

Retrieved on: 
Wednesday, March 6, 2024

SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Inc. magazine today revealed that Crosschq is No.7 on its fourth annual Inc. 5000 Regionals’ Pacific list, the most prestigious ranking of the fastest-growing private companies.

Key Points: 
  • SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Inc. magazine today revealed that Crosschq is No.7 on its fourth annual Inc. 5000 Regionals’ Pacific list, the most prestigious ranking of the fastest-growing private companies.
  • Born of the annual Inc. 5000 franchise, this highly competitive regional list represents a unique look at the most successful companies within the Pacific economy’s most dynamic segment–its independent small businesses.
  • Fitzsimmons continued, “Prior to Crosschq, establishing quality of hire as a corporate KPI was an insurmountable yet highly sought-after objective.
  • “The honorees in our Inc. 5000 network are the Who’s Who of private companies.

Global Bioenergies: strong reduction of the loss in 2023 thanks to a significant increase in commercial activity

Retrieved on: 
Wednesday, March 6, 2024

In the first half of 2023, Global Bioenergies successfully supplied several tons of Isonaturane™ to major players in the cosmetics industry, including L'Oréal.

Key Points: 
  • In the first half of 2023, Global Bioenergies successfully supplied several tons of Isonaturane™ to major players in the cosmetics industry, including L'Oréal.
  • Thanks to this unique innovation, cosmetic products, from make-up to skincare, gain in naturalness while guaranteeing customers the same level of performance.
  • In 2023 alone, the savings of 100 MWh are equivalent to the private consumption of all Global Bioenergies employees.
  • As a reminder, on the full-year report of 29 December 2023, the following assets appeared on the liquidity account:

Signature HealthCARE’s “Legislative Lady” Honored Nationally as an Advocate for the Long- Term Care Industry and Its Patrons for Nearly Three Decades

Retrieved on: 
Tuesday, March 5, 2024

“They are having a positive impact within their organizations and within the industry, benefiting colleagues, residents, patients, and clients.

Key Points: 
  • “They are having a positive impact within their organizations and within the industry, benefiting colleagues, residents, patients, and clients.
  • We are delighted to recognize their accomplishments and look forward to honoring them in person soon.”
    Lawmakers on both sides of the isle, know Kathy Gallin.
  • For the past 18 years, Kathy has taken on and pioneered legislative affairs, healthcare issues, and health care policies on behalf of Signature HealthCARE and its predecessor company , Home Quality Management.
  • 7 years prior, she was a litigation paralegal for a large multi-office law firm defending skilled nursing facilities throughout Florida.

EDAP Announces FDA Breakthrough Device Designation for Focal One® in the Treatment of Deep Infiltrating Rectal Endometriosis

Retrieved on: 
Monday, March 4, 2024

“This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.

Key Points: 
  • “This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives.
  • The Focal One system being granted a Breakthrough Device designation underscores the significance of this innovative development for DIE patients.
  • In January 2022, EDAP reported positive results from the Phase 2 Endo-HIFU-1R study (N=60) evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis, and this data was included in EDAP’s submission in consideration for receiving Breakthrough Device designation from the FDA.
  • In February 2024, EDAP announced the completion of enrollment in a Phase 3 study evaluating Focal One HIFU therapy for the treatment of deep infiltrating rectal endometriosis.

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

Retrieved on: 
Friday, March 1, 2024

Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."

Key Points: 
  • Dr. Sarel will be sharing with her expert colleagues insight and information on the topic of "Regulatory Challenges in the Development of an Extracellular Vesicles (EVs) - Based Clinical Product."
  • Dr. Sarel joins a prestigious lineup of speakers including representatives from leading exosome companies, e.g.
  • The summit will take place on April 23-25, 2024 in Boston, MA.
  • To learn more about the summit and to register, please visit the Conference Website .

Study Surmounts Barrier to Measuring Healthcare Worker Exposure to Workplace Violence

Retrieved on: 
Tuesday, February 27, 2024

OAKBROOK TERRACE, Illinois, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Workplace violence (WPV), including physical assaults and verbal threats, is a pervasive and significant issue for healthcare workers and organizations.

Key Points: 
  • OAKBROOK TERRACE, Illinois, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Workplace violence (WPV), including physical assaults and verbal threats, is a pervasive and significant issue for healthcare workers and organizations.
  • WPV directly harms healthcare workers and increases their anxiety, depression and staff turnover.
  • Rates of WPV are likely underestimated because past studies have mostly used surveys that rely on recall of past events.
  • A study featured in the March 2024 issue of The Joint Commission Journal on Quality and Patient Safety (JQPS) overcomes this important barrier by precisely measuring nurse and patient care assistant exposure rates to patient aggression in real time, shedding light on prevention and management measures.